Статья
ВЛИЯНИЕ ОБРАЗА ЖИЗНИ НА ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ В КАРДИОЛОГИЧЕСКОЙ ПРАКТИКЕ: ЧТО ДОЛЖЕН УЧИТЫВАТЬ ВРАЧ?
В статье представлен обзор данных касающихся влияния продуктов питания, лекарственных растений, алкоголя и курения на эффективность и безопасность лекарственных препаратов. Показано, что крайне нежелателен одновременный прием лекарственных средств и фитопрепаратов, которые разнонаправленно влияют на метаболизм лекарств в организме человека. Употребление алкоголя, в зависимости от длительности и интенсивности, также различно влияет на эффективность лекарственных средств. Компоненты табачного дыма значимо снижают эффективность многих лекарственных препаратов, активируя систему цитохромов. При выборе лекарственных средств следует отдавать предпочтение препаратам, имеющим минимальное лекарственное и пищевое взаимодействие.
1. Wilson DE, Van Vlack T, Schievink BP. Lifestyle factors in hypertension drug research: systematic analysis of articles in a leading cochrane report. Int J Hyperten 2014; http:// dx.doi.org/10.1155/2014/835716.
2. Hussain MS. Patient counseling about herbal-drug interactions. Afr J Tradit Complement Altern Med. 2011;8.
3. Simaan JA. Phytotherapy that doctors have to know. J Med Liban. 2009 October-December; 57 (4): 215-7.
4. Clinical pharmacology: textbook for high schools. Ed. Kukes VG. 4th edition. 2009. 1056
5. p. Russian (Клиническая фармакология: учебник для вузов. В. Г. К укес. 4-е издание. 2009. 1056 с).
6. Jáuregui-Garrido B, Jáuregui-Lobera I. Interactions between antiarrhythmic drugs and food Nutr. Hosp. 2012; 27 5 Sept.-Oct.
7. Tashenova AI. The transport system of P glycoprotein and pharmacokinetics of drugs. Biomedicine 2010; 4: 24-32. Russian (Ташенова А. И., Транспортная система гликопротеина Р и фармакокинетика лекарственных средств. Биомедицина, 2010; 4:
8. -32).
9. Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs Nutr J. 2007; 6: 33.
10. Roland PD, Nergard CS. A ginkgo of a bilob- effect, by-effects and interactions of drugs Tidsskr Also Laegeforen. 2012 on April 30; 132 (8): 956-9.
11. Ulbricht C, Chao W, Costa D, et al. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008 Dec; 9(10): 1063-120.
12. Izzo AA, Ernst E. Interactions between medicinal herbs and drugs: the updated systematic review. Drugs. 2009; 69 (13): 1777-98.
13. Chen W, Serag ES, Sneed KB, et al. Clinical grass interactions from usual drugs: from molecules to diseases. Med Chem flew. 2011; 18 (31): 4836-50.
14. Tsai HH, Lin HW, Lu YH, et al. A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PLoS One. 2013 May 9; 8(5): e64255.
15. SemenovaAE, Sergyenko IV. Farmacological view on tatin therapy. Ateroscleroz i dyslipidemii, 2013; 2: 4-18. Russian (Cеменова А.Е., Сергиенко И.В. Фармакологические аспекты терапии статинами. Атеросклероз и дислипидемии, 2013; 2: 4-18).
16. Drug interactions checker. http://www.drugs.com/drug_interactions.html. Дата обращения 26.12.15.
17. Brown RL, Dimond AR, Hulisz D, et al. Pharmacoepidemiology of potential alcoholprescription drug interactions among primary care patients with alcohol-use disorders. J Am Pharm Assoc 2007 Mar-Apr; 47(2): 135-9.
18. Cousins G, Galvin R, Flood M, et al. Potential for alcohol and drug interactions in older adults: evidence from the Irish longitudinal study on ageing. BMC Geriatr. 2014; Apr 27; 14: 57.
19. Immonen S, Valvanne J, Pitkälä KH. The prevalence of potential alcohol-drug interactions in older adults. Scand J Prim Health Care 2013; Jun; 31(2): 73-8.
20. Moore AA, Whiteman EJ, Ward KT. Risks of combined alcohol/medication use in older adults. Am J Geriatr Pharmacother. 2007; Mar; 5(1): 64-74.
21. Lukyanchuk VD, Shipulina OA. Interaction between alcohol and cardiovascular drugs Rational drug therapy 2006; 1:28-34. Russian (Лукьянчук В.Д, Шпулина О. А. Взаимодействие алкоголя и кардиоваскулярных препаратов Рациональная фармакотерапия 2006; 1: 28-34).
22. Belyakov KV. Interaction of alcohol with drugs. Consilium provisorum 2005; 5(3): 23-27.
23. Russian (Беляков К . В. Взаимодействие алкоголя с лекарственными препаратами. Consilium provisorum 2005; 5(3): 23-27).
24. Limas CJ, Guiha NH, Lekagul O, et al. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974; 49: 755-60.
25. Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014 Apr; 22(2): 83-94.
26. Koçak ND, Eren A, Boğa S, et al. Relapse Rate and Factors Related to Relapse in a 1-Year Follow-Up of Subjects Participating in a Smoking Cessation Program. Respir Care. 2015 Dec; 60(12): 1796-803.
27. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality—beyond established causes. N Engl J Med. 2015; 372: 631-40.
28. Sherman BW, Lynch WD. The association of smoking with medical treatment adherence in the workforce of a large employer. Abstract Metrics Get Permission 2014; 8: 477-86.
29. Lukina YV. Drugs and smoking. Rational pharmacotherapy in cardiology. 2005; 1: 31-6.
30. Russian (Лукина Ю. В. Лекарственные препараты и курение. Рациональная фармакотерапия в кардиологии. 2005; 1: 31-6).
31. Leonova MV. The effect of Smoking on the effectiveness of cardiovascular drugs. Consilium Medicum 2013; 15(1): 50-5. Russian (Леонова М . В. Влияние курения на эффективность кардиоваскулярных препаратов. Consilium Medicum 2013; 15(1): 50-5).
32. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007; 64(18): 1917-21.
33. Molden E, Spigset O. Tobacco smoking and drug interactions Tidsskr Nor Laegeforen. 2009; 129(7): 632-3.
34. Reims HM, Oparil S, Kjeldsen S, et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Pressure 2004; 13: 376-84.
35. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-68.
36. Gotto AM, Toth PP. Сomprehensive management of high risk cardiovascular patients. Сrc Press 2007..
37. Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006; 98(5): 577-9.
38. Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120: 2337-44.
39. Ferreiro JL, Bhatt DL, U eno M, et al. Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial. J Am Coll Cardiol. 2014; 63(8): 769-77.
40. Gurbel PA, et al. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307:2495-6.
41. Berger JS, et al. Smoking, Clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120: 2337-44.
42. Gagne JJ, Bykov K, Choudhry NK, et al. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ. 2013; 347: f5307. doi: 10.1136/bmj.f5307.
43. Riksen NP. Clopidogrel cannot yet be exclusively for smokers. Ned Tijdschr Geneeskd. 2014; 158: A7359.
44. Tarlovskaya EI, Koziolova NA, Chesnikova AI. An issue of drug interaction in cardiological practice: what shall physician be aware of? Russ J Cardiol. 2015; (12): 91-101. Russian (Тарловская Е.И., Козиолова Н.А., Чесникова А.И. Проблема лекарственного взаимодействия в кардиологической практике: что должен учитывать врач? Российский кардиологический журнал. 2015; (12): 91-101).